@HelenBranswell @TheLancet Is it not included in this? https://t.co/nCMUHgLuOH
@g26529063 @BadCOVID19Takes Nope, 100% survival vs 99.7% For the Oxford vaccine, zero people were hospitalized, and obviously zero died. So 0.0% deaths, vs 0.03% Your 95% is the number without even moderate symptoms, and your 5% difference survived. Facts
@CyrilPedia @florian_krammer You are right (MenACWY): https://t.co/yHvUhWCCu6
@aihsan_goker @cem_baykal Oxford aşısı https://t.co/DyqCl3so1H
@vaccinologie @vlanx0 Des publications, oui : https://t.co/0DbKWObSFS
📃Revisión: Las vacunas han de ser seguras y eficaces, especialmente, en los grupos de alto riesgo ➡️ The Lancet 2020. https://t.co/g717WrZpoK 📎 https://t.co/QmZL9KGcHn #COVID19 #COVID19SEMERGEN #MFyC #AtenciónPrimaria https://t.co/L81tk3Q66H
RT @TheLancet: Authors note that their new findings could be encouraging if the immune responses found in their study are associated with p…
RT @nikki_click: @UKActionteam This is the Oxford trial data https://t.co/ZxRtdaX6gG
RT @nikki_click: @UKActionteam This is the Oxford trial data https://t.co/ZxRtdaX6gG
RT @nikki_click: @UKActionteam This is the Oxford trial data https://t.co/ZxRtdaX6gG
@UKActionteam This is the Oxford trial data https://t.co/ZxRtdaX6gG
@TristanKamin Ici plus de détails . https://t.co/QnbESxKy5a
@TristanKamin Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial https://t.co/RWCSwzBGsz Ici l'étude Astra Zeneca.
@MikkiFerrugiaro @Gedk The point is that vaccine trials don't normally takes years because they're testing for long term effects, they take years because there are a lot of non-value adding steps they need to take such as waiting for people to sign up to t
@Hurtwoodsun @yox2814 @MattHancock https://t.co/88bDtBC4As Here you go
RT @jim0thy: @Hurtwoodsun @guus_real @MattHancock Here’s the results of the RCT. Please feel free to share your comments on it’s efficacy.…
@NinjaEconomics What we can say at this stage is your risk from getting the vaccine is significantly less than covid fatality risk. It's true we don't know about effects a year or more from now, in either case, but this much smaller test sample shows no ob
Reassuring safety of the Oxford COVID-19 vaccine (as expected to be honest) https://t.co/DlFGXTQcMb
RT @SEMERGENap: 📃Revisión: Las vacunas han de ser seguras y eficaces, especialmente, en los grupos de alto riesgo ➡️ The Lancet 2020. https…
📃Revisión: Las vacunas han de ser seguras y eficaces, especialmente, en los grupos de alto riesgo ➡️ The Lancet 2020. https://t.co/g717WrZpoK 📎 https://t.co/QmZL9KGcHn #COVID19 #COVID19SEMERGEN #MFyC #AtenciónPrimaria https://t.co/vcTMcG7uXb
They won't publish final findings for another year
Agree surveillance would be of huge value, and AZ/Oxford doing it in the UK Phase 3 trial as you know. It takes time to validate protocols/assays under GCP, adding complexity to large, already-complex, high-speed Ph3 programs. But agree w/basic point. http
@UniofOxford #COVID19 #vaccine shows similar immunogenicity among younger and older adults, say researchers. https://t.co/3ox5MRarDW Read the full paper here: https://t.co/rSZFSQIRVv #PharmaceuticalSciences #Lancet https://t.co/gAy9aC7bs4
RT @fedkukso: AZ/Oxford hasta ahora son los únicos que han publicado en una revista científica con revisión de pares (The Lancet) que su va…
RT @fedkukso: AZ/Oxford hasta ahora son los únicos que han publicado en una revista científica con revisión de pares (The Lancet) que su va…
RT @fedkukso: AZ/Oxford hasta ahora son los únicos que han publicado en una revista científica con revisión de pares (The Lancet) que su va…
@LucaAmb I'm afraid I don't know that and they don't seem to have disclosed that information yet. A paper on the previous phase of the trial which ended in August was just published (https://t.co/BIlduFCRX2), so my guess is that we will know in a couple of
@fsmpastapharian @IsraelNavasDur1 @HarryLeonard7 @RepThomasMassie This time with the link. Lots of detail. https://t.co/nCMUHgLuOH
👉In India, placebo is saline (not specified in protocol); 2 full doses (1 dose= 0.5 ml dose intramuscularly) in India. For adults: placebos in UK (MenACWY, MenACWY) & Brazil (MenACWY, saline). Different age groups w/ different dose regimen. App of ht
@w3myrem @martinfd78 @mlalanda Oldest 83 (Astra) https://t.co/8dwIgC7Wbe Lo de hasta 85 la de Pfizer ya te lo he puesto
@BernhardGeyer @Muster97732179 @HKgns81 Fallsterblichkeit nach Ioannidis/WHO 0,2% und für unter 70 jährige 0,05% Auf lancet ist die Studie für AstraZeneca verfügbar,... https://t.co/sEPl3Oz8DO
@calios1 @Dr_Ellie @KnightAyton @MattHancock @BarneyCalman @EveSimmns @BorisJohnson @AstraZeneca @OxfordVacGroup @susannareid100 @pfizer_news @CMO_England Of course. This is the one I first read from this I researched other articles. I genuinely was concer
RT @JMassano: Oxford/AstraZeneca: incluiu 240 pessoas com 70 anos ou mais. Resposta imunológica semelhante em TODOS os grupos etários. Foi…
RT @JMassano: Oxford/AstraZeneca: incluiu 240 pessoas com 70 anos ou mais. Resposta imunológica semelhante em TODOS os grupos etários. Foi…
RT @JMassano: Oxford/AstraZeneca: incluiu 240 pessoas com 70 anos ou mais. Resposta imunológica semelhante em TODOS os grupos etários. Foi…
👇🏼
RT @JMassano: Oxford/AstraZeneca: incluiu 240 pessoas com 70 anos ou mais. Resposta imunológica semelhante em TODOS os grupos etários. Foi…
Em Portugal começam a preparar o discurso para o completo falhanço da vacinação... Temos o que merecemos... @govpt @PSaserPS
RT @DavidQutob: Resultados de fase 2 con datos de seguridad de la vacuna de Oxford administrada en adultos sanos controlada con placebo. h…
RT @JMassano: Oxford/AstraZeneca: incluiu 240 pessoas com 70 anos ou mais. Resposta imunológica semelhante em TODOS os grupos etários. Foi…
Resultados de fase 2 con datos de seguridad de la vacuna de Oxford administrada en adultos sanos controlada con placebo. https://t.co/4VmAG69HJg
RT @JMassano: Oxford/AstraZeneca: incluiu 240 pessoas com 70 anos ou mais. Resposta imunológica semelhante em TODOS os grupos etários. Foi…
Aposto que os gajos de Oxford são fascistas
RT @JMassano: Oxford/AstraZeneca: incluiu 240 pessoas com 70 anos ou mais. Resposta imunológica semelhante em TODOS os grupos etários. Foi…
RT @mark_toshner: For those asking about safety in older populations, hot off press this am from Oxford ChadOx vaccine study- encouraging i…
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial https://t.co/ZkxD0frhOn
RT @JMassano: Oxford/AstraZeneca: incluiu 240 pessoas com 70 anos ou mais. Resposta imunológica semelhante em TODOS os grupos etários. Foi…
@DonDavies Which #CovidVaccine are you interested in getting? Which are in production? I'm inclined to wait for more #vaccine testing. Your bombastic tweets are the reason why I won't vote NDP. Be more thoughtful than impatient. Follow the science. ht
RT @JMassano: Oxford/AstraZeneca: incluiu 240 pessoas com 70 anos ou mais. Resposta imunológica semelhante em TODOS os grupos etários. Foi…
Without the statistical analysis plan, but at least a current version! Thx for finding this!
🦠
Trending on PubMed: Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. https://t.co/cQ0AEFMCiY
@Pajarobere @duvicq ¿Por qué inexistentes? Las vacunas no comienzan a existir durante su aprobación, existen ya candidatos de vacuna con suficientes datos incluso en revistas científicas como para ser optimistas https://t.co/H3oJpfzVyc
@Pediatria Si hay publicaciones, está por lo menos esta en @TheLancet respecto al estudio fase II/III de la de @AstraZeneca https://t.co/BTHtoz1hSz Y la FDA y las agencias Europeas tienen acceso privilegiado a mucha data
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial https://t.co/2AcF6L7vBE
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial - The Lancet https://t.co/HvIgaKiNsL
The Oxford vaccine study reported in the Lancet makes no mention of the use of vaccinomics or adversomics to detect potential autoimmune responses in trial participants. This information is vital and should have been submitted to the regulatory authority
RT @JMassano: Oxford/AstraZeneca: incluiu 240 pessoas com 70 anos ou mais. Resposta imunológica semelhante em TODOS os grupos etários. Foi…
RT @JMassano: Oxford/AstraZeneca: incluiu 240 pessoas com 70 anos ou mais. Resposta imunológica semelhante em TODOS os grupos etários. Foi…
Oxford/AstraZeneca: incluiu 240 pessoas com 70 anos ou mais. Resposta imunológica semelhante em TODOS os grupos etários. Foi segura e com menos efeitos adversos nos MAIS velhos (56 anos ou mais). Dizer que "não há dados" é simplesmente falso https://t.co/8
Articles about the Oxford vaccine https://t.co/EJ09VyKq8d https://t.co/cLM8KGD6cO #r4today
@rorysutherland Great question. I hope someone can help us out with that. I found two papers in Lancet. The first study was double-blind but the second one was single-blind. https://t.co/m5OWSImapr (Phase 1/2: October 15, 2020) https://t.co/uYFg4o2lCS
@hugosmarques @SexoGratweeto @otiagoandre os dados da AZ/OxUni tb e estão publicados: https://t.co/t9F2PBSZvY
@miguelcper @mjoaomarks queres do artigo mesmo? é do dia 18: https://t.co/t9F2PBSZvY
Um estudo publicado há uns dias no Lancet dá-nos alguma informação preliminar sobre os idosos, mas se formos ver os métodos do ensaio clínico, verificamos que excluem pessoas idosas com um mínimo de vulnerabilidade (Dalhousie Clinical Frailty Score de 4) h
one extra tiny note of confusion: in the Phase 2/3 protocol trial design, Group 4 sounds a lot like the low-dose/standard dose thing. It's about the right number of people, it's 18-55yos, just as the LD/SD group apparently was. See here, p127 https://t.co/
@joncoop194 @HelenKiddle @Coronavirusgoo1 Probably too much data to snapshot here, but the information's in a handy table here.... https://t.co/3jSsNhg5c1
@MattHancock @MHRAgovuk @UniofOxford @AstraZeneca Two paragraphs which are entirely mutually exclusive. Misleading word games from Hancock. The Oxford vaccine is NOT a coronavirus vaccine, it's a covid-19 vaccine. Remember the difference? It's important th
RT @eddwilson: Articles about the Oxford vaccine https://t.co/EJ09VyKq8d https://t.co/cLM8KGD6cO #r4today @lbc #PoliticsLive #wato
efficacy of this vaccine is warranted in all age groups and individuals with comorbidities. #COVIDSecondWave #VaccineSafety Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults … https://t.co/Y
Articles about the Oxford vaccine https://t.co/EJ09VyKq8d https://t.co/cLM8KGD6cO #r4today @lbc #PoliticsLive #wato
@grubstreetsteve No it isn't. See below link to Lancet article of how testing in over 55 demonstrates good immune response. https://t.co/RZ2hGQ8M3k
Would someone please do me a quick favour and see if you can access this link to the Oxford vaccines protocols. I managed it yesterday, but it doesn't seem to want to give me access today. Thank you. https://t.co/6nVpIEJK8u
@DeVore It has been tested in the over 55 though, see the Lancet peer reviewed article below. Although you're right he higher efficacy reported earlier in the week is in 55 and below https://t.co/RZ2hGQ8M3k
@Scott62115847 @GMB Incorrect. It has been. https://t.co/RZ2hGQ8M3k
@malini_aisola @gargolo @tudsy @WIRED That it's meningococcal vaccine (MenACWY) is consistent from trial registration https://t.co/lMO7zHG8MQ to the protocol https://t.co/SBCuAhrh5x to the recent results from phase 2 https://t.co/yY2020YJhT (It's a phase 2
@luckynostra @Reuters Here is the actual clinical study on Lancet of the Oxford vaccine. Notable that it is the only one published in a major journal whereas Pfizer and Moderna only have press releases. Only the Oxford vaccine has been made public for scie
RT @david_colquhoun: Good thread from @hildabast on Oxford-AstraZeneca vaccine. See her piece in Wired https://t.co/zkaqZuKpG6
Good thread from @hildabast on Oxford-AstraZeneca vaccine. See her piece in Wired https://t.co/zkaqZuKpG6
RT @DustyFootprints: @The_Oldfields @globalhlthtwit Have you read the Lancet paper that preceded the latest press release. The numbers I qu…
RT @fedkukso: AZ/Oxford hasta ahora son los únicos que han publicado en una revista científica con revisión de pares (The Lancet) que su va…
@EricBillyFR @jdflaysakier @wargonm Si, l'essai AstraZeneca a été publié. https://t.co/o7qNtTzRuK
@PotardDechaine @wargonm @jdflaysakier paradoxalement c'est AZN qui a publie le plus de données cliniques de sa PhII/III https://t.co/NXlOux1lSa
@LucreSnooker @cispt2 https://t.co/EEFOubAOzt page 170 Avent's product is 5e10 copies/dose (PCR) CBF’s product is 5e10 copies/dose (Abs260) Symbiosis’ product is 3.5–6.5e10 (Abs260), a ± 30% range to take into account process and method variabilities fish
@Cairo67Unedited Missing from NYT handwringin. AZN results are in fact scientifically stronger than those of Moderna & Pfizer. The latter don’t have any similar data for old adult.
@pieter_haeck Anderzijds is er wel deze fase 2 studie die zich specifiek richt op oudere populatie: https://t.co/L8ZiHCPu6c
Pfizer : https://t.co/iS70fFzUAB AstraZeneca : https://t.co/sGsN1PZv2w Moderna : https://t.co/Y7NWsA9Kn2 A l'heure actuelle, vous êtes toujours aussi bidon.
@Trade_Well @zeynep @hildabast Yes. Open access. https://t.co/0P2KQ0UjTq
@Laconic_doc @JaimeBorjas11 @WIRED Yes, it's been published: was published last week in appendix to the phase 2 results. I link to it @WIRED as it's pretty central to my post. Although they said it would be 4 trials https://t.co/SBCuAhrh5x I maintain an op
*Correction: AZ Protocol for UK/Brazil trial of ChAdOx1 nCoV-19 published in Appendix of https://t.co/ywW0KjOSla Caution: Trial is SINGLE-blind. Latest https://t.co/EoVmO56LCu is mismatched w/ half & full dose order. h\t @hildabast @malini_aisola.